Sadir Pharma Funds 200M for Biopharmaceuticals and Cancer Drugs

Saudi company Seder Pharma plans to invest 200 million riyals to develop four production lines for the localization of biopharmaceuticals in the Kingdom. It is working on localizing six biopharmaceuticals. Their plans include starting local production of these medicines next year, followed by expanding manufacturing efforts with a focus on cancer drugs and insulin. The company has localized around 40 cancer medication products, which are now being exported to six countries, aiming to strengthen drug security, provide affordable medicines, and boost their export capabilities in the future. Additionally, the second phase of insulin localization aims to produce three types of biosimilar insulin and support its availability locally, thereby narrowing the gap in this category of medicines.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل